REG - Creo Medical Group - Capital Markets Day

Creo MedicalAnnouncement

07/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231107:nRSG5504Sa&default-theme=true

RNS Number : 5504S  Creo Medical Group PLC  07 November 2023

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Capital Markets Day

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy, announces that it is hosting its Capital
Markets Day today at the offices of Deutsche Numis, London at 3pm GMT.

 

The Company will provide greater detail on the commercial and clinical
progress of its products and will feature presentations from a number of NHS
clinicians who are using Creo's products in practice.  The agenda of the
event will include presentations from:

 

·    Dr Sal Khalid, Consultant Gastroenterologist and Clinical Lead for
Endoscopy at The Pennine Acute Hospitals NHS Trust: "How Speedboat Submucosal
Dissection is helping Oldham tackle bowel cancer"

·   Dr Adolfo Parra-Blanco, Consultant Gastroenterologist, Hepatologist,
Nottingham NHS Treatment Centre: "Why Speedboat is so effective at reducing
patient complications in the Upper GI tract"

·    Mr Tom Routledge, Consultant Thoracic Surgeon, Guy's and St. Thomas'
NHS Foundation Trust: "Creo Medical - A surgeon's perspective"

 

The event is open to institutional investors, sell-side analysts and media
only. To request a place at the event, please contact Walbrook PR on +44 (0)20
7933 8780 or creo@walbrookpr.com.

 

No new material information will be disclosed during the event.

 

-Ends-

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cavendish Capital Markets Limited                  +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume (NOMAD)

 Nigel Birks / Harriet Ward (Corporate Broking)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                      +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                         Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFZMGMNVDGFZM